PDF DatasheetHuman Anti-CD6 Antibody Product Attributes
CD6 Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in CD6 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in cells in the white pulp in spleen, lymphoid tissue in appendix and non-germinal center cells in the lymph node and tonsil. More moderate antibody staining intensity was present in cells in the white pulp in spleen, lymphoid tissue in appendix and non-germinal center cells in the lymph node and tonsil. Low, but measureable presence of CD6 could be seen inhematopoietic cells in the bone marrow. We were unable to detect CD6 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD6 expression as measured by anti-CD6 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| CD6 Variability | + | + | + | + | + | + | + | + | + | ++ | + | + | + | + | + | + | + | + | ++ | + |
| CD6 General Information | |
|---|---|
| Alternate Names | |
| CD6, Cluster of Differentiation 6 | |
| Molecular Weight | |
| 90-130kDa | |
| Chromosomal Location | |
| 11q12.2 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | CD6 |
| Entrez Gene ID | 923 |
| Ensemble Gene ID | ENSG00000013725 |
| RefSeq Protein Accession(s) | XP_011543664, XP_006718803, XP_006718804, XP_011543662, NP_006716, NP_001241680, XP_006718802, XP_006718801, NP_001241679 |
| RefSeq mRNA Accession(s) | XM_011545362, NM_006725, XM_006718740, XM_011545360, XM_006718739, NM_001254751, NR_045638, XM_006718738, XM_006718741, NM_001254750 |
| RefSeq Genomic Accession(s) | NC_018922, NC_000011 |
| UniProt ID(s) | P30203, Q8N4Q7, Q6AZ88 |
| UniGene ID(s) | P30203, Q8N4Q7, Q6AZ88 |
| HGNC ID(s) | 1691 |
| Cosmic ID(s) | CD6 |
| KEGG Gene ID(s) | hsa:923 |
| PharmGKB ID(s) | PA26230 |
| General Description of CD6. | |
| CD6 is a type I transmembrane glycoprotein that contains a 24-amino acid signal sequence, three extracellular scavenger receptor cysteine-rich (SRCR) domains, a membrane-spanning domain, a 44-amino acid cytoplasmic domain. The CD6 glycoprotein is tyrosine phosphorylated during TCR-mediated T cell activation. CD6 shows significant homology to CD5. CD6 is present on mature thymocytes, peripheral T cells, a subset of B cells. Antibodies to CD6 are used to deplete T cells from bone marrow transplants to prevent graft versus host disease. | |
There are no reviews yet.